The AZD1222 vaccine, developed by the British-Swedish company AstraZeneca and the University of Oxford, showed an average efficacy of 70 percent. This was reported on the website of the pharmaceutical company.
The trials tested two options for administering the vaccine. In the first case, more than 2.7 thousand people AZD1222 was injected first in a half dose, and a month later in full, and the effectiveness was 90 percent. The variant with the introduction of two full doses with a difference of a month was tested on 9 thousand people and the result was only 62 percent. The combined analysis of both dosing regimens showed an average efficacy of 70 percent.
Also, in the course of research, it turned out that protection against COVID-19 appears 14 days after receiving two doses of the vaccine. There were no severe cases of the disease in participants in the AZD1222 trial.
In September, AstraZeneca suspended trials of its COVID-19 vaccine after one study participant contracted transverse myelitis (inflammation of the spinal cord). Later, in October, it became known of the death of one of the volunteers for the national trials of the AstraZeneca vaccine. It turned out that the test participant received a placebo and the company continued testing.
